Multi-center trial of Carvedilol(Dilatrend)treatment for resistant renal parenchymal hypertension
- VernacularTitle:卡维地洛治疗顽固性肾实质性高血压多中心临床观察
- Author:
Yu WANG
;
Xiaomei LI
;
Haiyan WANG
- Publication Type:Journal Article
- Keywords:
Carvedilol;
Resistant renal parenchymal hypertension;
Treatment
- From:
Chinese Journal of Practical Internal Medicine
2006;0(22):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of carvedilol treatment for resistant renal parenchymal hypertension.Methods In this multi-center,open label,self-controlled trial,the enrolled resistant renal parenchymal hypertension patients stopped the use of ?-blocker and ?-blocker and took carvedilol 12.5 mg/d as initial dose and tittered to maximal dose of 50mg/d for 8 weeks.Other treatment was unchanged during the period.Results Among 183 patients enrolled,176 patients were followed up for 8 weeks.The systolic/diastolic BP decreased from(164.0?20.8)/(98.7?12.5)mm Hg to(140.0?14.2)/(84.5?24.7)mm Hg(both P
